A US Food and Drug Administration (FDA) advisory panel has backed Grail’s Galleri blood test, which aims to detect multiple types of cancer through a single blood test. The panel concluded that the test’s potential benefits outweigh its risks for eligible patients.
During Wednesday’s meeting, the panel voted unanimously that the test met the required safety standard. However, members expressed some differences over its effectiveness. The decision marks an important development for Grail as it seeks regulatory approval for its cancer screening technology.
Quick Fact
| Detail | Information |
|---|---|
| What Happened | FDA advisory panel backs Grail's Galleri cancer blood test |
| Company | Grail |
| Test Name | Galleri |
| Location | United States |
| Safety Vote | 10 to 0 in favour |
| Effectiveness Vote | 6 to 4 in favour |
| Benefits and Risks | 7 to 2 in favour, with one abstention |
| Purpose | Screening for multiple types of cancer |
| Current Status | Advisory panel recommendation, final FDA decision pending verification |
FDA Panel Backs Grail's Galleri Cancer Blood Test
The FDA advisory panel has supported Grail’s Galleri blood test, which aims to screen for several types of cancer using a single blood sample. The panel reviewed the test’s safety, effectiveness and potential benefits.
During the meeting, all 10 voting members supported the test’s safety. They agreed that Galleri provided reasonable assurance of safety under the proposed conditions.
However, the panel expressed different views about its effectiveness. Six members supported the effectiveness assessment, while four voted against it
FDA Panel Voting Results
Safety
10 to 0
All 10 members voted in favour.
Effectiveness
6 to 4
Six members voted in favour and four opposed.
Benefits Outweigh Risks
7 to 2
Seven members voted in favour, two opposed and one abstained.
How Does Grail's Galleri Blood Test Work?
Grail developed Galleri as a multi cancer screening test. It uses a blood sample to look for signals associated with cancer.
Unlike conventional screening tests that target specific cancers, Galleri aims to identify signals from multiple cancer types through one test.
However, a positive screening result does not automatically confirm cancer. Patients may need additional medical tests to determine whether cancer is present.
Why Is the FDA Panel's Decision Important?
The panel’s recommendation marks a significant regulatory development for Grail’s cancer screening technology.
The unanimous safety vote indicates that all 10 voting members supported the proposed safety assessment. Meanwhile, the effectiveness vote showed a difference of opinion among panel members.
Multi cancer screening tests could offer another way to identify cancer. However, doctors must also consider the possibility of inaccurate results and unnecessary follow up tests.
FDA Panel Backs Galleri Test
Until the FDA announces its decision, Galleri’s regulatory status should not be confused with full FDA approval.
The FDA advisory panel has backed Grail’s Galleri blood test, supporting its safety and finding that its benefits outweigh its risks under the proposed conditions. However, members expressed differing views about its effectiveness.
The recommendation represents an important step in the regulatory review of multi cancer screening technology. The FDA’s final decision remains a separate matter.
